Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5–6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster
The main objective of this study was to assess in 5–6-year-old French children ( n=234) the persistence of antibodies induced by a primary series vaccination (at 2–4 months of age) and a first booster (at 12–16 months of age) with a pentavalent two-component acellular pertussis combined vaccine (DTa...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2004-03, Vol.22 (11), p.1415-1422 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1422 |
|---|---|
| container_issue | 11 |
| container_start_page | 1415 |
| container_title | Vaccine |
| container_volume | 22 |
| creator | Mallet, Eric Matisse, Noëlle Mathieu, Nicolas Langue, Jacques Boisnard, Florence Soubeyrand, Benoı̂t |
| description | The main objective of this study was to assess in 5–6-year-old French children (
n=234) the persistence of antibodies induced by a primary series vaccination (at 2–4 months of age) and a first booster (at 12–16 months of age) with a pentavalent two-component acellular pertussis combined vaccine (DTacP-IPV-Hib; Pentavac
®). The second objective was to evaluate in these 5–6-year-old French children the safety and the immunogenicity of a tetravalent acellular pertussis combined vaccine (DTacP-IPV; Tetravac
®) given as second booster.
Results: Seroprotective antibody levels against diphtheria, tetanus, types 1–3 poliomyelitis and PRP were maintained 4–5 years after primary-vaccination and first booster with Pentavac
®. As expected, anti-PT antibodies levels were low, suggesting that children were not colonised by
Bordetella pertussis. The second booster with Tetravac
® was well tolerated and elicited a strong booster response for all antigens.
Conclusion: acellular pertussis combined vaccine, used in primary-vaccination, could be considered as having the same priming effect and the same efficacy as whole cell pertussis vaccine. |
| doi_str_mv | 10.1016/j.vaccine.2003.10.025 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71796444</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X03007734</els_id><sourcerecordid>17912917</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-ccc0a62a26a3ca3e9fb3585dfb3f4cf6ec420b7247218965e83421881f0a38353</originalsourceid><addsrcrecordid>eNqVksGK1EAQhqMo7rj6CEpfFIXN2J2kk4wXWRZ1hAUvCt5CpVOZqSHpjt2dkXjyHXxDn8TOTmC9LZ6qKb7681flj6Jngq8FF_mbw_oISpHGdcJ5Gnprnsj70UqURRonUpQPohVP8izOBP92Fj127sA5l6nYPIrOhOR5KvNsda-61J5q00xsQOvIedQKGeyAtPOsoWHv92gJLphHD3p0FzPoRxfY8DQdmX7Cjjw5BrphW8DeDHvqRsdIt92I-icg89OArGavtlS_Dn0m__z6nccTgo1N1zAVBhqLmkHr0bLBUg92YqcNwZPRN-It2WCqNsbN1A_yewbBjvZwhC4Upkxfh5M0DBR23diBvXW7qOFbRn0_arNDTYr8dKPsTYcW5tVNGzTDrvZ_NNmOjrP7cAPmUJmguLh8Ej1soXP4dKnn0dcP779cbePrzx8_XV1exypLEh8rpTjkCSQ5pApS3LR1KkvZhNJmqs0xYLwukqxIRLnJJZZpFl6laDmkZSrT8-jlSXew5vuIzlc9udkwaDSjqwpRbPIsy-4EAyeSjSgCKE-gssY5i221_JZK8GqOYHWolvWrOYJzO0QwzD1fPjDWPTa3U0vmAvBiAcAp6Nr57uT-4XIuZJYG7t2Jw3C3I6GtnKI5ng1ZVL5qDN1h5S-H6ghc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17912917</pqid></control><display><type>article</type><title>Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5–6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Mallet, Eric ; Matisse, Noëlle ; Mathieu, Nicolas ; Langue, Jacques ; Boisnard, Florence ; Soubeyrand, Benoı̂t</creator><creatorcontrib>Mallet, Eric ; Matisse, Noëlle ; Mathieu, Nicolas ; Langue, Jacques ; Boisnard, Florence ; Soubeyrand, Benoı̂t ; The Pentavac ; Study Group ; Pentavac Study Group</creatorcontrib><description>The main objective of this study was to assess in 5–6-year-old French children (
n=234) the persistence of antibodies induced by a primary series vaccination (at 2–4 months of age) and a first booster (at 12–16 months of age) with a pentavalent two-component acellular pertussis combined vaccine (DTacP-IPV-Hib; Pentavac
®). The second objective was to evaluate in these 5–6-year-old French children the safety and the immunogenicity of a tetravalent acellular pertussis combined vaccine (DTacP-IPV; Tetravac
®) given as second booster.
Results: Seroprotective antibody levels against diphtheria, tetanus, types 1–3 poliomyelitis and PRP were maintained 4–5 years after primary-vaccination and first booster with Pentavac
®. As expected, anti-PT antibodies levels were low, suggesting that children were not colonised by
Bordetella pertussis. The second booster with Tetravac
® was well tolerated and elicited a strong booster response for all antigens.
Conclusion: acellular pertussis combined vaccine, used in primary-vaccination, could be considered as having the same priming effect and the same efficacy as whole cell pertussis vaccine.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2003.10.025</identifier><identifier>PMID: 15063564</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Acellular pertussis vaccine ; Antibodies - analysis ; Antibody Formation - immunology ; Antibody persistence ; Applied microbiology ; Bacterial diseases ; Biological and medical sciences ; Booster ; Bordetella pertussis ; Child ; Child, Preschool ; Clostridium tetani ; Corynebacterium diphtheriae ; Diphtheria-Tetanus-Pertussis Vaccine - adverse effects ; Diphtheria-Tetanus-Pertussis Vaccine - immunology ; Ent and stomatologic bacterial diseases ; Female ; France - epidemiology ; Fundamental and applied biological sciences. Psychology ; Haemophilus influenzae ; Haemophilus influenzae type b - immunology ; Haemophilus Vaccines - adverse effects ; Haemophilus Vaccines - immunology ; Human bacterial diseases ; Human viral diseases ; Humans ; Immunization, Secondary ; Immunologic Memory - immunology ; Infectious diseases ; Male ; Medical sciences ; Microbiology ; Poliovirus Vaccines - adverse effects ; Poliovirus Vaccines - immunology ; Vaccination ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Combined - adverse effects ; Vaccines, Combined - immunology ; Viral diseases ; Viral diseases of the nervous system</subject><ispartof>Vaccine, 2004-03, Vol.22 (11), p.1415-1422</ispartof><rights>2003 Elsevier Ltd</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-ccc0a62a26a3ca3e9fb3585dfb3f4cf6ec420b7247218965e83421881f0a38353</citedby><cites>FETCH-LOGICAL-c422t-ccc0a62a26a3ca3e9fb3585dfb3f4cf6ec420b7247218965e83421881f0a38353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.vaccine.2003.10.025$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64387</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15601543$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15063564$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mallet, Eric</creatorcontrib><creatorcontrib>Matisse, Noëlle</creatorcontrib><creatorcontrib>Mathieu, Nicolas</creatorcontrib><creatorcontrib>Langue, Jacques</creatorcontrib><creatorcontrib>Boisnard, Florence</creatorcontrib><creatorcontrib>Soubeyrand, Benoı̂t</creatorcontrib><creatorcontrib>The Pentavac</creatorcontrib><creatorcontrib>Study Group</creatorcontrib><creatorcontrib>Pentavac Study Group</creatorcontrib><title>Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5–6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>The main objective of this study was to assess in 5–6-year-old French children (
n=234) the persistence of antibodies induced by a primary series vaccination (at 2–4 months of age) and a first booster (at 12–16 months of age) with a pentavalent two-component acellular pertussis combined vaccine (DTacP-IPV-Hib; Pentavac
®). The second objective was to evaluate in these 5–6-year-old French children the safety and the immunogenicity of a tetravalent acellular pertussis combined vaccine (DTacP-IPV; Tetravac
®) given as second booster.
Results: Seroprotective antibody levels against diphtheria, tetanus, types 1–3 poliomyelitis and PRP were maintained 4–5 years after primary-vaccination and first booster with Pentavac
®. As expected, anti-PT antibodies levels were low, suggesting that children were not colonised by
Bordetella pertussis. The second booster with Tetravac
® was well tolerated and elicited a strong booster response for all antigens.
Conclusion: acellular pertussis combined vaccine, used in primary-vaccination, could be considered as having the same priming effect and the same efficacy as whole cell pertussis vaccine.</description><subject>Acellular pertussis vaccine</subject><subject>Antibodies - analysis</subject><subject>Antibody Formation - immunology</subject><subject>Antibody persistence</subject><subject>Applied microbiology</subject><subject>Bacterial diseases</subject><subject>Biological and medical sciences</subject><subject>Booster</subject><subject>Bordetella pertussis</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Clostridium tetani</subject><subject>Corynebacterium diphtheriae</subject><subject>Diphtheria-Tetanus-Pertussis Vaccine - adverse effects</subject><subject>Diphtheria-Tetanus-Pertussis Vaccine - immunology</subject><subject>Ent and stomatologic bacterial diseases</subject><subject>Female</subject><subject>France - epidemiology</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Haemophilus influenzae</subject><subject>Haemophilus influenzae type b - immunology</subject><subject>Haemophilus Vaccines - adverse effects</subject><subject>Haemophilus Vaccines - immunology</subject><subject>Human bacterial diseases</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunization, Secondary</subject><subject>Immunologic Memory - immunology</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Poliovirus Vaccines - adverse effects</subject><subject>Poliovirus Vaccines - immunology</subject><subject>Vaccination</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Combined - adverse effects</subject><subject>Vaccines, Combined - immunology</subject><subject>Viral diseases</subject><subject>Viral diseases of the nervous system</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVksGK1EAQhqMo7rj6CEpfFIXN2J2kk4wXWRZ1hAUvCt5CpVOZqSHpjt2dkXjyHXxDn8TOTmC9LZ6qKb7681flj6Jngq8FF_mbw_oISpHGdcJ5Gnprnsj70UqURRonUpQPohVP8izOBP92Fj127sA5l6nYPIrOhOR5KvNsda-61J5q00xsQOvIedQKGeyAtPOsoWHv92gJLphHD3p0FzPoRxfY8DQdmX7Cjjw5BrphW8DeDHvqRsdIt92I-icg89OArGavtlS_Dn0m__z6nccTgo1N1zAVBhqLmkHr0bLBUg92YqcNwZPRN-It2WCqNsbN1A_yewbBjvZwhC4Upkxfh5M0DBR23diBvXW7qOFbRn0_arNDTYr8dKPsTYcW5tVNGzTDrvZ_NNmOjrP7cAPmUJmguLh8Ej1soXP4dKnn0dcP779cbePrzx8_XV1exypLEh8rpTjkCSQ5pApS3LR1KkvZhNJmqs0xYLwukqxIRLnJJZZpFl6laDmkZSrT8-jlSXew5vuIzlc9udkwaDSjqwpRbPIsy-4EAyeSjSgCKE-gssY5i221_JZK8GqOYHWolvWrOYJzO0QwzD1fPjDWPTa3U0vmAvBiAcAp6Nr57uT-4XIuZJYG7t2Jw3C3I6GtnKI5ng1ZVL5qDN1h5S-H6ghc</recordid><startdate>20040329</startdate><enddate>20040329</enddate><creator>Mallet, Eric</creator><creator>Matisse, Noëlle</creator><creator>Mathieu, Nicolas</creator><creator>Langue, Jacques</creator><creator>Boisnard, Florence</creator><creator>Soubeyrand, Benoı̂t</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T5</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20040329</creationdate><title>Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5–6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster</title><author>Mallet, Eric ; Matisse, Noëlle ; Mathieu, Nicolas ; Langue, Jacques ; Boisnard, Florence ; Soubeyrand, Benoı̂t</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-ccc0a62a26a3ca3e9fb3585dfb3f4cf6ec420b7247218965e83421881f0a38353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Acellular pertussis vaccine</topic><topic>Antibodies - analysis</topic><topic>Antibody Formation - immunology</topic><topic>Antibody persistence</topic><topic>Applied microbiology</topic><topic>Bacterial diseases</topic><topic>Biological and medical sciences</topic><topic>Booster</topic><topic>Bordetella pertussis</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Clostridium tetani</topic><topic>Corynebacterium diphtheriae</topic><topic>Diphtheria-Tetanus-Pertussis Vaccine - adverse effects</topic><topic>Diphtheria-Tetanus-Pertussis Vaccine - immunology</topic><topic>Ent and stomatologic bacterial diseases</topic><topic>Female</topic><topic>France - epidemiology</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Haemophilus influenzae</topic><topic>Haemophilus influenzae type b - immunology</topic><topic>Haemophilus Vaccines - adverse effects</topic><topic>Haemophilus Vaccines - immunology</topic><topic>Human bacterial diseases</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunization, Secondary</topic><topic>Immunologic Memory - immunology</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Poliovirus Vaccines - adverse effects</topic><topic>Poliovirus Vaccines - immunology</topic><topic>Vaccination</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Combined - adverse effects</topic><topic>Vaccines, Combined - immunology</topic><topic>Viral diseases</topic><topic>Viral diseases of the nervous system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mallet, Eric</creatorcontrib><creatorcontrib>Matisse, Noëlle</creatorcontrib><creatorcontrib>Mathieu, Nicolas</creatorcontrib><creatorcontrib>Langue, Jacques</creatorcontrib><creatorcontrib>Boisnard, Florence</creatorcontrib><creatorcontrib>Soubeyrand, Benoı̂t</creatorcontrib><creatorcontrib>The Pentavac</creatorcontrib><creatorcontrib>Study Group</creatorcontrib><creatorcontrib>Pentavac Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mallet, Eric</au><au>Matisse, Noëlle</au><au>Mathieu, Nicolas</au><au>Langue, Jacques</au><au>Boisnard, Florence</au><au>Soubeyrand, Benoı̂t</au><aucorp>The Pentavac</aucorp><aucorp>Study Group</aucorp><aucorp>Pentavac Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5–6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2004-03-29</date><risdate>2004</risdate><volume>22</volume><issue>11</issue><spage>1415</spage><epage>1422</epage><pages>1415-1422</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>The main objective of this study was to assess in 5–6-year-old French children (
n=234) the persistence of antibodies induced by a primary series vaccination (at 2–4 months of age) and a first booster (at 12–16 months of age) with a pentavalent two-component acellular pertussis combined vaccine (DTacP-IPV-Hib; Pentavac
®). The second objective was to evaluate in these 5–6-year-old French children the safety and the immunogenicity of a tetravalent acellular pertussis combined vaccine (DTacP-IPV; Tetravac
®) given as second booster.
Results: Seroprotective antibody levels against diphtheria, tetanus, types 1–3 poliomyelitis and PRP were maintained 4–5 years after primary-vaccination and first booster with Pentavac
®. As expected, anti-PT antibodies levels were low, suggesting that children were not colonised by
Bordetella pertussis. The second booster with Tetravac
® was well tolerated and elicited a strong booster response for all antigens.
Conclusion: acellular pertussis combined vaccine, used in primary-vaccination, could be considered as having the same priming effect and the same efficacy as whole cell pertussis vaccine.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>15063564</pmid><doi>10.1016/j.vaccine.2003.10.025</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2004-03, Vol.22 (11), p.1415-1422 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71796444 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Acellular pertussis vaccine Antibodies - analysis Antibody Formation - immunology Antibody persistence Applied microbiology Bacterial diseases Biological and medical sciences Booster Bordetella pertussis Child Child, Preschool Clostridium tetani Corynebacterium diphtheriae Diphtheria-Tetanus-Pertussis Vaccine - adverse effects Diphtheria-Tetanus-Pertussis Vaccine - immunology Ent and stomatologic bacterial diseases Female France - epidemiology Fundamental and applied biological sciences. Psychology Haemophilus influenzae Haemophilus influenzae type b - immunology Haemophilus Vaccines - adverse effects Haemophilus Vaccines - immunology Human bacterial diseases Human viral diseases Humans Immunization, Secondary Immunologic Memory - immunology Infectious diseases Male Medical sciences Microbiology Poliovirus Vaccines - adverse effects Poliovirus Vaccines - immunology Vaccination Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Combined - adverse effects Vaccines, Combined - immunology Viral diseases Viral diseases of the nervous system |
| title | Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5–6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T17%3A17%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibody%20persistence%20against%20diphtheria,%20tetanus,%20pertussis,%20poliomyelitis%20and%20Haemophilus%20influenzae%20type%20b%20(Hib)%20in%205%E2%80%936-year-old%20children%20after%20primary%20vaccination%20and%20first%20booster%20with%20a%20pentavalent%20combined%20acellular%20pertussis%20vaccine:%20immunogenicity%20and%20tolerance%20of%20a%20tetravalent%20combined%20acellular%20pertussis%20vaccine%20given%20as%20a%20second%20booster&rft.jtitle=Vaccine&rft.au=Mallet,%20Eric&rft.aucorp=The%20Pentavac&rft.date=2004-03-29&rft.volume=22&rft.issue=11&rft.spage=1415&rft.epage=1422&rft.pages=1415-1422&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2003.10.025&rft_dat=%3Cproquest_cross%3E17912917%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17912917&rft_id=info:pmid/15063564&rft_els_id=S0264410X03007734&rfr_iscdi=true |